Pair Name | Corilagin, Paclitaxel | ||
Phytochemical Name | Corilagin (PubChem CID: 73568 ) | ||
Anticancer drug Name | Paclitaxel (PubChem CID: 36314 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Drug Name | Paclitaxel |
Adverse Reactions | Bronchospasmodic dyspnoea, hypotension, peripheral neuropathy and bone, joint and muscle aches and pains. This was inferred cold nature anticancer drug. |
Recommendations | Hot: Dimocarpus longan; Terminalia chebula; Astragalus membranaceus; Lycopodium japonicum |
Reference | Malignant tumors in the era of immunotherapy based on traditional Chinese medicine's "cold and hot theory" Construction of integrated traditional Chinese and Western medicine treatment paradigm[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine,2023,32(12):1712-1716. DOI:10.3969/j.issn.1008-8849.2023.12.022. ref_link |
Pair Name | Corilagin, Paclitaxel | |||
Disease Info | [ICD-11: 2C73] | Ovarian cancer | Investigative | |
Biological Phenomena | Inhibition-->Glycolysis | |||
Gene Regulation | Down-regulation | Expression | CD44 | hsa960 |
Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
Down-regulation | Expression | SNAI1 | hsa6615 | |
Down-regulation | Expression | STAT3 | hsa6774 | |
In Vitro Model | KOV3.ip1 | Ovarian serous cystadenocarcinoma | Homo sapiens (Human) | CVCL_0C84 |
HEY | High grade ovarian serous adenocarcinoma | Homo sapiens (Human) | CVCL_0297 | |
HO-8910 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_6868 | |
Result | Our observations indicate that corilagin sensitized epithelial ovarian cancer cells to paclitaxel and carboplatin treatment by primarily inhibiting Snail-glycolysis pathways. Corilagin is a herbal medicine with low toxic effects to normal cells, particularly hepatoprotective, and may be an ideal complimentary medicine when combined with highly toxic chemotherapeutic agents. |
No. | Title | Href |
---|---|---|
1 | Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways. Oncol Rep. 2017 Oct;38(4):2464-2470. doi: 10.3892/or.2017.5886. | Click |